Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib

被引：14
|
作者：
Ikezoe, Takayuki [1 ]
Togitani, Kazuto [1 ]
Tasaka, Taizo [2 ]
Nishioka, Chie [1 ]
Yokoyama, Akihito [1 ]
机构：
[1] Kochi Univ, Dept Hematol & Resp Med, Nanko Ku, Kochi 7838505, Japan
[2] Kawasaki Med Sch, Dept Lab Med, Okayama, Japan
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 08期
关键词：
TYROSINE KINASE INHIBITOR; LEUKEMIA;
D O I：
10.1016/j.leukres.2010.02.024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E200 / E201
页数：2
相关论文
共 50 条
  • [1] Nilotinib in imatinib-resistant patients
    Fricker, Janet
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (13) : 1888 - 1888
  • [2] Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML
    Zhu, Guang-rong
    Ji, Ou
    Ji, Jian-min
    Zhang, Ya-cheng
    Wu, Yu
    Yu, Hui
    Jiang, Peng-Jun
    Shen, Qun
    ACTA HAEMATOLOGICA, 2012, 127 (03) : 152 - 155
  • [3] Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
    Deguchi, Yasuyuki
    Kimura, Shinya
    Ashihara, Eishi
    Niwa, Tomoko
    Hodohara, Keiko
    Fujiyama, Yoshihide
    Maekawa, Taira
    LEUKEMIA RESEARCH, 2008, 32 (06) : 980 - 983
  • [4] Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: A case report
    Tan, D
    Hwang, W
    Ng, HJ
    Goh, YT
    Tan, P
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (01) : 75 - 77
  • [5] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    Gruber, F. X.
    Ernst, T.
    Porkka, K.
    Engh, R. A.
    Mikkola, I.
    Maier, J.
    Lange, T.
    Hochhaus, A.
    LEUKEMIA, 2012, 26 (01) : 172 - 177
  • [6] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    Kantarjian, Hagop
    Giles, Francis
    Wunderle, Lydia
    Bhalla, Kapil
    O'Brien, Susan
    Wassmann, Barbara
    Tanaka, Chiaki
    Manley, Paul
    Rae, Patricia
    Mietlowski, William
    Bochinski, Kathy
    Hochhaus, Andreas
    Griffin, James D.
    Hoelzer, Dieter
    Albitar, Maher
    Dugan, Margaret
    Cortes, Jorge
    Alland, Leila
    Ottmann, Oliver G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24): : 2542 - 2551
  • [7] Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: A case report
    Tan D.
    Hwang W.
    Ng H.J.
    Goh Y.T.
    Tan P.
    International Journal of Hematology, 2004, 80 (1) : 75 - 77
  • [8] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    F X Gruber
    T Ernst
    K Porkka
    R A Engh
    I Mikkola
    J Maier
    T Lange
    A Hochhaus
    Leukemia, 2012, 26 : 172 - 177
  • [9] Treatment of hypereosinophilic syndrome with imatinib mesilate
    Gleich, GJ
    Leiferman, KM
    Pardanani, A
    Tefferi, A
    Butterfield, JH
    LANCET, 2002, 359 (9317): : 1577 - 1578
  • [10] Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
    Loveman, E.
    Cooper, K.
    Bryant, J.
    Colquitt, J. L.
    Frampton, G. K.
    Clegg, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (23) : 1 - +
12345